ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $36.50 Average Price Target from Brokerages

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have earned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $36.50.

A number of equities analysts have recently commented on the company. BTIG Research initiated coverage on ABIVAX Société Anonyme in a research note on Monday, May 20th. They issued a “buy” rating and a $43.00 price objective on the stock. Piper Sandler started coverage on ABIVAX Société Anonyme in a research report on Monday, April 29th. They set an “overweight” rating and a $42.00 target price on the stock. Guggenheim began coverage on ABIVAX Société Anonyme in a research note on Monday, April 29th. They set a “buy” rating and a $50.00 price target on the stock. Finally, Laidlaw started coverage on ABIVAX Société Anonyme in a research report on Monday, July 29th. They issued a “buy” rating and a $48.00 price objective for the company.

ABIVAX Société Anonyme Price Performance

Shares of NASDAQ ABVX traded down $0.04 during trading hours on Friday, hitting $11.19. 100,251 shares of the stock were exchanged, compared to its average volume of 84,537. ABIVAX Société Anonyme has a one year low of $7.99 and a one year high of $17.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.08 and a quick ratio of 4.08. The company’s 50 day moving average is $12.89 and its 200 day moving average is $13.60.

Institutional Trading of ABIVAX Société Anonyme

Several institutional investors have recently bought and sold shares of ABVX. BNP Paribas Financial Markets acquired a new stake in shares of ABIVAX Société Anonyme in the 1st quarter valued at $81,000. Capstone Investment Advisors LLC acquired a new position in shares of ABIVAX Société Anonyme in the 4th quarter worth approximately $618,000. Ghisallo Capital Management LLC bought a new stake in ABIVAX Société Anonyme during the 4th quarter worth approximately $642,000. Kennedy Capital Management LLC increased its holdings in ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after purchasing an additional 31,331 shares in the last quarter. Finally, Rosalind Advisors Inc. bought a new position in ABIVAX Société Anonyme in the 1st quarter valued at $5,411,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.